The Nottingham Haematological Malignancy Diagnostics Service (HMDN) provides an integrated haematopathology diagnostic service which covers histopathology, diagnostic cytology, flow cytometry, cytogenetics and Molecular pathology. This allows for a multi-parameter approach to integrated reporting and samples will be processed according to specific diagnostic pathways, based on clinical symptoms or (assumed) diagnosis provided to us. Close collaboration within HMDN ensures that information from all relevant modalities is integrated into the final report with an aim of reaching an accurate diagnosis in line with the 2016 WHO classification of tumours of the haematopoietic and lymphoid tissues. Diagnostic pathways have been consulted upon and agreed through the East Midlands Clinical Advisory Group (ECAG).
The results of each laboratory section will be presented as a comprehensive integrated report, compiled by collating and interpreting all the results together. Individual results may also be reported separately if clinically urgent. This integrated approach is intended to facilitate the classification and prognostic determination of the disease, and to help the clinician to design an appropriate management strategy.
The HMDN service is UKAS accredited to ISO15189:2012 standards within the NUH Cellular Pathology scope (8162) and strives to maintain a high level of quality throughout its processes.
Please see the full list of accredited tests on the UKAS website https://www.ukas.com/search-accredited-organisations/.
For more information please refer to our handbook.